Opportunities and Benefits of CETA for Canada’s Pharmaceutical Exporters

PDF Version (615 KB)

Why export to the EU?

How does CETA benefit Canadian pharmaceutical companies?

Opportunities for investment in Canada’s pharmaceutical sector through CETA

Canada is an attractive destination for pharmaceutical research and manufacturing, offering:

Under CETA:

Mutual recognition of pharmaceutical good manufacturing practices

Labour mobility

Government procurement

Top 5 suppliers of pharmaceutical products to the EU% of Import Market Share
United States    37.8%
Switzerland36.0%
Singapore4.6%
China4.2%
Israel3.9%
Canada (8th)2.1%

Source: Eurostat (2018)

Under CETA, Canadian exporters of pharmaceutical products can now enjoy the advantages created from the agreement over competitors based in countries that do not have a preferential trade agreement in force with the EU.

Non-CETA related factors to keep in mind when exporting pharmaceutical products to the EU

For more detail on how CETA benefits your company, contact a Trade Commissioner today.

Date Modified: